Previous Close | 36.23 |
Open | 35.87 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 35.60 - 36.30 |
52 Week Range | 20.24 - 56.80 |
Volume | |
Avg. Volume | 622,156 |
Market Cap | 4.353B |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | 151.02 |
EPS (TTM) | 0.24 |
Earnings Date | May 02, 2022 - May 06, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 71.08 |
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights. “The Phase 1 study of DNL919 (ATV:TREM2) is now underway, making this our third BBB Transport Vehicle (TV)-enabled program,